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Abstract Earlier studies indicated that human fibroblast
growth factor receptor (FGFR)-3 IIIc was activated equally well
by both FGF-1 and FGF-2. In contrast, murine FGFR-3 IIIc was
preferentially activated by FGF-1. To address this issue, we
determined the ligand-binding specificity of human FGFR-3 IIIc
in comparison with human FGFR-1 IIIc. By equilibrium binding
human FGFR-3 IIIc preferentially bound FGF-1 with high
affinity, whereas FGFR-1 IIIc bound both FGF-1 and -2 with
high affinity. By competition binding using FGF-1, -2, -4, or -6,
FGF-1 competed more efficiently than the other FGFs. These
results suggest that like the murine FGFR-3 III, FGF-1 is a
preferred ligand for human FGFR-3 IIIc.
z 1997 Federation of European Biochemical Societies.
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1. Introduction
Fibroblast growth factors (FGF) are a family of polypep-
tide mitogens consisting of at least nine members (FGF-1^9)
[1,2]. FGFs are expressed in speci¢c temporal and spatial
patterns and are involved in developmental processes, angio-
genesis, wound healing, and tumorigenicity. FGFs bind to
high-a¤nity receptors on cell surface and activate signal
transduction pathways. The cloning of FGF receptors identi-
¢ed four di¡erent genes encoding the FGFR family of recep-
tor tyrosine kinases (FGFR-1^4) [3^5]. Alternatively spliced
forms of FGFR-1, -2, and -3 have been identi¢ed. The alter-
native splicing may a¡ect the ligand-binding speci¢city, bio-
logical activity, or localization of the receptors. Heparin or
cell-surface heparan sulfate proteoglycans (HSPG) serve as
low-a¤nity receptors and potentiate the binding and function
of FGFs [6^8].
Signals from ligand-activated FGFRs appear to control dif-
ferentiation as well as proliferation. Mutations in these recep-
tors have indicated that they may control the di¡erentiation
of speci¢c cell types during development. Point mutations of
the genes encoding human FGFR-1, -2, or -3 have been
shown to cause di¡erent syndromes that involve defects in
bone development [9,10]. In particular, point mutations that
activate FGFR-3 [11^13] may cause dwar¢sm such as achon-
droplasia [14,15], hypochondroplasia [16,17] or thanatophoric
dysplasia [18,19]. To address the underlying mechanism be-
hind these syndromes, it is necessary to understand the role
that FGFR-3 can play in normal human development. In
order to do this, it is necessary to identify which of the
FGF family members can serve as physiologically relevant
ligands for this receptor.
Using a calcium e¥ux assay performed with microinjected
Xenopus oocytes, our previous studies showed that human
FGFR-3 IIIc can be activated with similar e¤ciencies by
both FGF-1 and -2 [20]. However, it was subsequently re-
ported that mouse FGFR-3 IIIc preferentially binds FGF-1
over FGF-2 [21]. There are three possibilities for the discrep-
ancy between these two studies. The ¢rst possibility is that the
calcium e¥ux assay may not be able to distinguish the di¡er-
ence in a¤nities of FGF-1 and -2 to human FGFR-3 IIIc.
The second possibility is that these results may re£ect spe-
cies-speci¢c di¡erence between human and mouse FGFR-
3 IIIc. The third possibility is that in di¡erent cell types, dif-
ferent composition of cell surface HSPGs may a¡ect the bind-
ing a¤nity of FGF-2 to FGFR-3 IIIc. To distinguish between
these possibilities, we have determined the ligand-binding spe-
ci¢city of human FGFR-3 IIIc in comparison with FGFR-
1 IIIc using L6 cells engineered to express FGFR-3 IIIc or
-1 IIIc. We found that, like mouse FGFR-3 IIIc, human
FGFR-3 IIIc also preferentially bound FGF-1 with a high
a¤nity.
2. Materials and methods
2.1. Cell culture and transfection of L6 cells
Rat L6 skeletal muscle myoblasts and L6-derived transfectant lines
were grown in DMEM (Life Technologies, Grand Island, NY) with
8% fetal calf serum. Before subcloning of the human FGFR-3 IIIc
cDNA [20] into an expression vector, the sequences upstream of the
start codon were removed to increase the e¤ciency of translation.
Full-length FGFR-3 IIIc cDNA was subcloned into the HindIII site
of the retroviral vector pLNCX [22]. This placed the receptor directly
downstream of cytomegalovirus immediate-early promoter element.
The constructed plasmid was named pLhR3-5.
Transfection of L6 cells was carried out by using the calcium phos-
phate method. The cells were seeded at 3U10
6
cells per 10-cm dish
1 day before transfection. On the day of transfection, the DNA sol-
ution containing 20 Wg DNA, 125 mM calcium chloride, and 1U BBS
(BES-bu¡ered saline, 50 mM BES, pH 6.95, 280 mM NaCl, and 1.5
mM Na2HPO4) was added slowly to the cells dropwise. The cells
were incubated with the DNA overnight at 37³C in a 3% CO
2
incu-
bator. Two days after transfection, we split the cells and selected
G418-resistant clones with complete media containing 500 Wg/ml of
Geneticin (Life Technologies). Two weeks after transfection, G418-
resistant colonies were picked with cloning cylinders. Expression of
FGFR-3 IIIc in individual clones was determined by Western blot
with the anti-FGFR-3 monoclonal antibody 8.34.
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2.2. Antibodies
The anti-FGFR-1 antisera £g-2B were raised against the
peptide SSGEDSVFSHEPLPEE, the human FGFR-1 C-terminal
penultimate sequence. The anti-FGFR-3 monoclonal antibody
8.34 was raised against bacterially expressed polypeptides encom-
passing amino acids 94^255 of the extracellular domain of human
FGFR-3.
2.3. Western blot
For Western blot, the cells were lysed in lysis bu¡er (20 mM Tris,
pH 7.6, 150 mM NaCl, 50 mM NaF, 1 mM Na
3
VO
4
, 5 mM benza-
midine, 1 mM EDTA, 10 Wg/ml leupeptin, 10 Wg/ml aprotinin, 1 mM
phenylmethylsulfonyl £uoride, and 1% Nonidet P-40), clari¢ed,
and the protein concentrations in the lysates were determined by
BCA method (Pierce, Rockford, IL). Aliquots of the lysates (75
Wg) of each sample were mixed with sample bu¡er, boiled, and frac-
tionated on an SDS-7.5% polyacrylamide gel. Protein was transferred
to nitrocellulose membranes (Schleicher and Schuell, Keene, NH)
by electroblotting. Non-speci¢c binding sites were blocked with
blocking bu¡er (3% BSA in PBS, 1 mM EDTA, 1 mM sodium
vanadate) for 1 h at room temperature. Membranes were then in-
cubated with the appropriate anti-FGFR antiserum diluted in
blocking bu¡er for 1 h at room temperature. Membranes were
washed with PBST (PBS, 0.1% Tween 20) and subsequently incubated
with anti-mouse Ig- or anti-rabbit Ig- horseradish peroxidase-
linked whole antibody (Amersham, Arlington Heights, IL) at a
dilution of 1:2500 in PBS plus 5% non-fat dry milk, and reactivity
was determined by the ECL chemiluminescence reaction (Amer-
sham).
2.4. Growth factors and radio-iodination
Recombinant human FGF-2 was a kind gift of D. Moscatelli (New
York University, NY) or purchased from Promega (Madison, WI).
Recombinant human FGF-4 was kindly provided by C. Basilico (New
York University, NY). Recombinant human FGF-6 was kindly pro-
vided by F. Coulier (Institut National de la Sante et de la Recherche
Medicale, Marseille, France). Recombinant human FGF-1 and FGF-
2 were radio-iodinated using the chloramine T method. The speci¢c
activity of the radiolabeled ligand was determined by radio-isotope
dilution using the respective unlabeled competitor. The speci¢c activ-
ity of [
125
I]FGF-1 was 750 000 cpm/ng and the speci¢c activity of
[
125
I]FGF-2 was 130 000 cpm/ng.
2.5. Binding of FGF
The binding assay was performed as follows. Fibronectin-coated
24-well plates (Collaborative Research) containing 1U10
5
cells/well
were placed on ice, and the wells were rinsed twice with cold binding
bu¡er. Plates were incubated on ice with 1 ml of ice-cold binding
bu¡er for 20 min, followed by 2 h at 4³C with serial dilutions of
the [
125
I]FGF in cold binding bu¡er. Non-speci¢c binding was ob-
tained using the same serial dilutions but in the presence of 20 Wg/
ml of non-radioactive FGF-1. After incubation, the cells were placed
on ice, rinsed once with ice-cold binding bu¡er, twice with ice-cold
PBS, and then solubilized in 0.25 ml of 1 N NaOH at 37³C for 15
min. When [
125
I]FGF-2 was used, the cells were placed on ice after
incubation, rinsed once with binding bu¡er, once with PBS, once with
2 M NaCl in 20 mM HEPES, pH 7.5, and then solubilized in 0.25 ml
of 1 N NaOH at 37³C for 15 min. The lysates were counted in a
Q-counter.
For competition of the binding of [
125
I]FGF-1 with non-radioactive
FGFs, we used 10 ng/ml of [
125
I]FGF-1 with serial dilutions of non-
radioactive FGFs, and followed the procedure as described above.
3. Results
3.1. Expression of FGFRs in L6 cells
To determine the ligand binding speci¢city of human
FGFR-3 IIIc, we transfected cDNAs encoding either
FGFR-3 IIIc or -1 IIIc into L6 cells. We used human
FGFR-1 IIIc as a control since its ligand binding character-
istics are well known. L6 cells were chosen because they do
not express any endogenous FGFRs. Cell lines stably ex-
pressed FGFR-3 or -1 were selected as described in Section
2. The selected cloned were screened by Western blot analysis
with receptor-speci¢c antibodies for FGFR-1 and -3. Fig. 1
shows the expression of FGFR-1 and -3 in two cell clones,
L£g17 and LR3-19. The receptors are detected as a 150-
(FGFR-1) and a 130-kDa protein (FGFR-3). Since these
two cell clones expressed roughly equivalent receptor numbers
as judged by scatchard analysis (see below), they were chosen
for the experiments described in this study.
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Fig. 1. Western blot analysis of FGFR-1 and -3 expression. L6neo represents L6 cells which was transfected with the expression vector alone.
L£g17 represents a clone of L6 cells which stably express human FGFR-1 IIIc. LR3-19 represents a clone of L6 cells which stably express hu-
man FGFR-3 IIIc. These three di¡erent cells were lysed. The lysates were resolved by SDS-PAGE and blotted with receptor-speci¢c antibodies
as indicated in the ¢gure. The bands of mature forms of FGFR-1 and -3 are indicated with arrows. The lower molecular weight species are
likely the immature forms of the receptors with incomplete glycosylation.
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3.2. FGF-1, but not FGF-2, binds to FGFR-3 IIIc with a high
a¤nity
To determine whether FGF-1 and -2 bind to FGFR-3 IIIc
with similar a¤nity, we performed equilibrium binding of
[
125
I]FGF-1 and [
125
I]FGF-2 on the FGFR-3 expressing
LR3-19 cells and the FGFR-1 expressing L£g17 cells. The
binding of
125
I-labeled FGFs to these cells was saturatable,
except for the low level binding of [
125
I]FGF-2 to LR3-19
(Fig. 2, insets). The results were subsequently analyzed by
Scatchard analysis (Fig. 2). The results show that FGF-1
binds to FGFR-3 with a K
d
of 190 pM, in contrast FGF-2
binds with very low a¤nity with a K
d
of at least 1300 pM. In
contrast, control experiments demonstrated that FGF-1 and
FGF-2 bound to FGFR-1 with very similar K
d
s of 310 and
280 pM, respectively. The receptor numbers per cell on LR3-
19 and L£g22 are 39 000 and 53 000, respectively. These re-
sults suggest that FGF-1, but not FGF-2, binds to FGFR-
3 IIIc with a high a¤nity, whereas both FGF-1 and -2 binds
to FGFR-1 IIIc with high a¤nities.
3.3. FGF-1 binds to FGFR-3 IIIc with a higher a¤nity than
FGF-2, -4, and -6
To extend this analysis we determined the relative binding
a¤nity of di¡erent FGF family members to human FGFR-
3 IIIc, using competition experiments. By competing the bind-
ing of [
125
I]FGF-1 to LR3-19 with di¡erent concentrations of
unlabeled FGF-1, -2, -4, or -6, we found that unlabeled FGF-
1 competed for the binding most e¤ciently among these four
FGFs, unlabeled FGF-2 and -4 competed the binding less
e¤ciently than unlabeled FGF-1, and unlabeled FGF-6 had
very little e¡ect on competition of the binding (Fig. 3). Un-
labeled FGF-1 can compete 50% of [
125
I]FGF-1 binding at a
concentration of 3 nM, whereas unlabeled FGF-2, -4, or -6
could not compete 50% of [
125
I]FGF-1 binding at concentra-
tions up to 100 nM (Fig. 3). These results suggest that FGF-1
binds to FGFR-3 IIIc with a higher a¤nity than FGF-2, -4,
and -6. Thus among these FGF family members, FGF-1 was
the only ligand found which bound to human FGFR-3 IIIc
with a high a¤nity.
4. Discussion
The current study was undertaken to address the issue of
the binding of FGF-2 to human and murine FGFR-3 IIIc.
Analysis of ligand binding using L6 cells engineered to express
human FGFR-3 IIIc indicated that this receptor preferentially
binds FGF-1 over FGF-2. These results are in agreement with
the results of ligand binding of soluble mouse FGFR-3 IIIc
performed with an in vitro system [21]. Previous reports had
indicated that human FGFR-3 can be activated similarly by
FGF-1 and -2 in a calcium e¥ux assay performed with Xeno-
pus oocytes microinjected with mRNA encoding the receptor
[20]. The discrepancy we have noted between activation [20]
and binding speci¢city is similar to that recently described for
mouse FGFR-3 IIIc [23]. It is presently unclear why this dis-
crepancy exists. It may re£ect e¡ects due to the expression of
di¡erent heparan sulfate proteoglycans on di¡erent cell types
which may in£uence ligand binding and receptor signaling.
Although the composition of cell surface HSPGs of Xenopus
oocytes may in£uence the binding a¤nities of FGF-1 and -2
to human FGFR-3, we feel it is more likely that this assay
amy have been unable to distinguish the di¡erence in binding
a¤nities between FGF-1 and -2 at the high concentrations of
FGF that were used in this assay in comparison to the ex-
pression levels of the receptors [20] The studies described in
this report, using cell lines with de¢ned receptor numbers,
allowed a more accurate determination of ligand-binding af-
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Fig. 3. Competition of Binding of [
125
I]FGF-1 to FGFR-3 IIIc L6
Cells. LR3-19 cells were incubated with 0.625 nM of [
125
I]FGF-1 in
the presence of di¡erent concentrations of unlabeled FGF-1, -2, -4,
or -6. The percent of maximum binding was calculated by dividing
the counts of radioactivity measured in the presence of unlabeled li-
gands by the counts measured in the absence of unlabeled ligands.
Fig. 2. Scatchard analysis of binding of [
125
I]FGF-1 and [
125
I]FGF-
2 to L6 cells expressing FGFR-3 IIIc or -1 IIIc. This ¢gure shows
Scatchard analysis for the binding of (A) [
125
I]FGF-1 and (B)
[
125
I]FGF-2 to FGFR-3 (b) and FGFR-1 (a) expressed in LR3-19
and L£g22 cells, respectively.
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¢nity and demonstrated that like the murine FGFR-3 IIIc
receptor the human FGFR-3 IIIc receptor preferentially binds
FGF-1 over FGF-2.
The results from the competition experiments showed that
among unlabeled FGF-1, -2, -4, and -6, only unlabeled FGF-1
can e¤ciently compete the binding of [
125
I]FGF-1 to FGFR-
3 IIIc expressed in L6 cells. Although there are no other com-
prehensive studies on ligand binding by human FGFR-3, oth-
er reports have addressed some aspects of the activation of
FGFR-3. For example, FGF-3 was found not to bind FGFR-
3 [24,25] BaF3 cells engineered to express di¡erent splicing
variants of murine FGF receptors have been used to address
activation of the receptors by FGF-1^9, [23]. These studies
demonstrated that the recently described FGF-8 and -9 can
signi¢cantly activate mouse FGFR-3 IIIc. This raises the pos-
sibility that, in addition to FGF-1, -8 and -9 may also be
physiologically relevant ligands for human FGFR-3 IIIc.
This possibility can be tested when the human FGF-8 and
-9 proteins become available.
FGFRs have been implicated in several human diseases, in
particular those genetic disorders that e¡ect bone develop-
ment. For example, three di¡erent mutations in FGFR-3
have been described that e¡ect dwar¢sm to varying degrees.
All three mutations are caused by point mutations within the
FGFR-3 protein which give rise to constitutively activated
receptors. The severity of the disease was found to re£ect
the degree of activation of the receptor. In the most common
form of the disease, namely achondroplasia, the receptor is
only partially activated and it can still be activated further by
the addition of ligand. Hence in developing a full understand-
ing of the role of FGFR-3 in these human diseases, as well as
during normal development, it is essential to identify the phys-
iologically relevant ligands. This study was undertaken to re-
solve the apparent discrepancy between the binding of murine
and human FGFR-3 IIIc receptors to FGF-2. The results
demonstrate that like the murine FGFR-3 IIIc receptor,
FGF-1 binds to human FGFR-3 IIIc receptor with a high
a¤nity whereas FGF-2 does not. This indicates that there is
no species di¡erence between the binding abilities of the hu-
man and murine receptors and thus it is likely that studies on
murine receptors can be extrapolated to the human situation.
This is an important consideration in the development of
murine models for the human diseases.
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